Viral and inflammatory markers in cerebrospinal fluid of patients with HIV‐1‐associated neurocognitive impairment during antiretroviral treatment switch

The aim of the study was to evaluate HIV‐1 viral load (VL) and inflammatory markers in cerebrospinal fluid (CSF) and neurocognitive performance in patients with neurocognitive impairment (NCI) while they were receiving tenofovir (TDF)/ emtricitabine (FTC)/efavirenz (EFV) and after switching to a regimen with enhanced central nervous system (CNS) penetrability.

[1]  B. Clotet,et al.  Interruptions of Antiretroviral Therapy in HIV Infection : Are they Detrimental to Neurocognitive Functioning ? , 2015 .

[2]  M. Hernán,et al.  Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions , 2014, Neurology.

[3]  R. Haubrich,et al.  Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  M. Ticchioni,et al.  Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? , 2014, AIDS.

[5]  B. Clotet,et al.  Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection , 2014, AIDS.

[6]  J. Mankowski,et al.  Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain , 2013, AIDS.

[7]  S Spudich,et al.  HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. , 2012, Cold Spring Harbor perspectives in medicine.

[8]  G. Annoni,et al.  Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation , 2012, Clinical & developmental immunology.

[9]  B. Clotet,et al.  Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning? , 2010, Journal of NeuroVirology.

[10]  C. Yiannoutsos,et al.  Clinical validation of the NeuroScreen , 2005, Journal of NeuroVirology.

[11]  V. Calvez,et al.  Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms , 2010, AIDS (London).

[12]  D. Cooper,et al.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. , 2010, The Journal of infectious diseases.

[13]  Anders Karlsson,et al.  Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.

[14]  D. Helsel.  Nondetects and data analysis : statistics for censored environmental data , 2005 .

[15]  Robert K. Heaton,et al.  Predictive Validity of Global Deficit Scores in Detecting Neuropsychological Impairment in HIV Infection , 2004, Journal of clinical and experimental neuropsychology.

[16]  I. Grant,et al.  Initial Validation of a Screening Battery for the Detection of HIV-Associated Cognitive Impairment , 2004, The Clinical neuropsychologist.

[17]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[18]  J. Bert Keats,et al.  Statistical Methods for Reliability Data , 1999 .

[19]  D. Fuchs,et al.  Cerebrospinal fluid neopterin concentrations in central nervous system infection. , 1993, The Journal of infectious diseases.

[20]  R. Price,et al.  Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection , 1990, Annals of neurology.

[21]  Eric N. Miller,et al.  HIV‐1 infection , 1990, Neurology.

[22]  E. Werner,et al.  Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. , 1989, AIDS.